Fabbrizi, Maria Rita http://orcid.org/0000-0002-5156-1575
Nickson, Catherine M.
Hughes, Jonathan R. http://orcid.org/0000-0002-6420-2504
Robinson, Emily A.
Vaidya, Karthik http://orcid.org/0009-0003-9378-8318
Rubbi, Carlos P.
Kacperek, Andrzej
Bryant, Helen E. http://orcid.org/0000-0003-2720-7020
Helleday, Thomas http://orcid.org/0000-0002-7384-092X
Parsons, Jason L. http://orcid.org/0000-0002-5052-1125
Funding for this research was provided by:
RCUK | MRC | Medical Research Foundation (MR/V028944/1)
U.S. Department of Health & Human Services | National Institutes of Health (1R01CA256854)
North West Cancer Research Fund (CR1197)
Swedish Cancer Foundation (22-2108S)
Article History
Received: 6 October 2023
Revised: 2 February 2024
Accepted: 6 February 2024
First Online: 17 February 2024
Competing interests
: TH is listed as an inventor on US patent no. WO2019166639A1, which covers OGG1 inhibitors. The patent is fully owned by a nonāprofit public foundation, the Thomas Helleday Foundation for Medical Research, and TH is a member of the foundation board. TH is a shareholder of Oxcia AB, a company that holds a license to WO2019166639A1. All other authors declare no competing interests.